ARVN

Arvinas Inc

Add to Watchlist

Advanced Chart

9.370

+0.160(+1.740%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

9.550

Open

9.310

VWAP

9.42

Vol

1.70M

Mkt Cap

644.39M

Low

9.110

Amount

16.02M

EV/EBITDA(TTM)

Total Shares

68.43M

-416.41M

EV/OCF(TTM)

P/S(TTM)

2.47

Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

42.22M

+66.89%

-1.004

+3.51%

42.65M

-44.24%

-1.074

+119.16%

56.00M

-45.32%

-1.161

+70.73%

Estimates Revision

The market is revising Downward the revenue expectations for Arvinas, Inc. (ARVN) for FY2025, with the revenue forecasts being adjusted by -3.41% over the past three months. During the same period, the stock price has changed by -47.62%.

Revenue Estimates for FY2025

Revise Downward

-3.41%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-16.16%

In Past 3 Month

Stock Price

Go Down

-47.62%

In Past 3 Month

20 Analyst Rating

262.22% Upside

Wall Street analysts forecast ARVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARVN is 33.94 USD with a low forecast of 10.00 USD and a high forecast of 81.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

15 Buy

5 Hold

0 Sell

Strong Buy

262.22% Upside

Current: 9.370

Low

10.00

Averages

33.94

High

81.00

262.22% Upside

Current: 9.370

Low

10.00

Averages

33.94

High

81.00

Goldman Sachs

Paul Choi

Hold

Maintains

$15 → $12

2025-04-17

Reason

Goldman Sachs

Paul Choi

Price Target

$15 → $12

2025-04-17

Maintains

Hold

Reason

Truist Securities

Joon Lee

Strong Buy

Maintains

$65 → $21

2025-04-09

Reason

Truist Securities

Joon Lee

Price Target

$65 → $21

2025-04-09

Maintains

Strong Buy

Reason

Truist analyst Joon Lee lowered the firm's price target on Arvinas to $21 from $65 and keeps a Buy rating on the shares as part of a broader research note on Biotech. The firm expects Arvinas to seek Vepdeg FDA approval but believes a label restricted to ESR1mut pts is likely for monotherapy, and Truist is updating its estimates to reflect a revised commercialization potential for Vepdeg resulting in peak sales of $1B vs. $1.8B consensus, the analyst tells investors in a research note.

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$81

2025-04-07

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$81

2025-04-07

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$81

2025-03-14

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$81

2025-03-14

Reiterates

Strong Buy

Reason

Guggenheim

Michael Schmidt

Strong Buy

Maintains

$57 → $32

2025-03-13

Reason

Guggenheim

Michael Schmidt

Price Target

$57 → $32

2025-03-13

Maintains

Strong Buy

Reason

Guggenheim analyst Michael Schmidt lowered the firm's price target on Arvinas to $32 from $57 and keeps a Buy rating on the shares after updating the firm's model and estimates following the announcement of topline results from the company's Phase 3 VERITAC-2 clinical trial of ER-degrader vepdegestrant. Following the data, the firm is increasing its monotherapy success probability, lowering its odds of success assumption in second-line metastatic breast cancer as part of combinations in all-comers to 30% from 50% and removing its first-line mBC estimates, the analyst noted.

Morgan Stanley

Terence Flynn

Hold

Maintains

$48 → $12

2025-03-13

Reason

Morgan Stanley

Terence Flynn

Price Target

$48 → $12

2025-03-13

Maintains

Hold

Reason

Morgan Stanley lowered the firm's price target on Arvinas (ARVN) to $12 from $48 and keeps an Equal Weight rating on the shares after the company and partner Pfizer (PFE) announced topline data from the Phase 3 VERITAC-2 study for vepdegestrant monotherapy in metastatic breast cancer. The trial in second-line and later mBC demonstrated a benefit in ESR1-mutants, but not the broader population, notes the analyst, who lowered the firm's Vepdeg 2035 sales estimate and now models 2035 risk-adjusted sales of $520M, down from $2.9B previously. The firm still projects a Vepdeg launch in 2026, but now assumes as its base case that Vepdeg will be used in patients only with ESR1-mutations and who progressed on CDK4/6i treatments.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Arvinas Inc (ARVN.O) is -2.28, compared to its 5-year average forward P/E of 76.43. For a more detailed relative valuation and DCF analysis to assess Arvinas Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

76.43

Current PE

-2.28

Overvalued PE

456.99

Undervalued PE

-304.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-15.40

Current EV/EBITDA

1.51

Overvalued EV/EBITDA

31.77

Undervalued EV/EBITDA

-62.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

28.92

Current PS

3.30

Overvalued PS

55.93

Undervalued PS

1.91

Financials

Annual

Quarterly

FY2024Q4

YoY :

-237.35%

59.20M

Total Revenue

FY2024Q4

YoY :

-64.79%

-58.20M

Operating Profit

FY2024Q4

YoY :

-70.87%

-45.10M

Net Income after Tax

FY2024Q4

YoY :

-75.10%

-0.63

EPS - Diluted

FY2024Q4

YoY :

+1.44%

-84.40M

Free Cash Flow

FY2024Q4

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2024Q4

YoY :

-77.81%

-99.13

FCF Margin - %

FY2024Q4

YoY :

-83.72%

-76.18

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

74.4K

USD

3-6

Months

771.6K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

565.0K

Volume

6-9

Months

0.0

Volume

0-12

Months

1.0M

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.9M

Volume

Months

6-9

0.0

Volume

Months

0-12

2.3M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

74.4K

USD

3-6

Months

771.6K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ARVN News & Events

Events Timeline

2025-04-28 (ET)

2025-04-28

06:49:25

Arvinas reports data from preclinical combination studies of ARV-393

2025-04-04 (ET)

2025-04-04

07:09:17

Arvinas presents first-in-human data from ARV-102 trial

2025-02-11 (ET)

2025-02-11

06:09:02

Arvinas announces anticipated upcoming milestones

News

9.5

04-28Newsfilter

PinnedArvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

9.0

04-23Newsfilter

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

9.0

04-21Newsfilter

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting